Skip to main content
Clinical Trials/NCT01760577
NCT01760577
Completed
N/A

Comparing Effects of Intraarticular Botulinum Toxin A Versus Hyaluronate Plus Rehabilitation Exercise in Patients With Unilateral Ankle Osteoarthritis

Kaohsiung Veterans General Hospital.1 site in 1 country70 target enrollmentMay 2010

Overview

Phase
N/A
Intervention
Botulinum Toxin A (Allergan, Inc, Irvine CA)
Conditions
Ankle Osteoarthritis
Sponsor
Kaohsiung Veterans General Hospital.
Enrollment
70
Locations
1
Primary Endpoint
Ankle Osteoarthritis Scale (AOS) score
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The purpose of this study is to compare the effects of intraarticular Botulinum Toxin A versus intraarticular hyaluronate plus rehabilitation exercise in patients with ankle osteoarthritis.

Detailed Description

Recent pilot studies report that intraarticular injection of Botulinum Toxin A into painful joints of patients with various types of arthritis leads to significant and durable improvement in pain and function and is safe to use. To date, there is no published literature that evaluate the effects of intraarticular Botulinum Toxin A in the treatment of ankle OA. Sun el al reported that 3 or 5 weekly injection of hyaluronate may improve pain and physical function in patients with ankle OA and the treatment effects may last for 6 months. The effect of one injection of hyaluronate plus exercise had never been studied. The purpose of this study is to compare the effects of intraarticular Botulinum Toxin A versus intraarticular hyaluronate plus rehabilitation exercise for patients with ankle OA.

Registry
clinicaltrials.gov
Start Date
May 2010
End Date
November 2012
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Shu-Fen Sun

MD

Kaohsiung Veterans General Hospital.

Eligibility Criteria

Inclusion Criteria

  • an age of 20-85 years with diagnosis of ankle osteoarthritis
  • unilateral ankle pain that had lasted for at least 6 months, with no significant benefit from conservative treatment or with an inability to tolerate the side effects of medications
  • ankle radiographs taken within 6 months equivalent to grade 2 on the Kellgren-Lawrence grading system
  • a current total Ankle Osteoarthritis Scale (AOS) score of \>3 and \< 9 (possible range, 0-10)
  • a normal activity level-i.e., not bedridden or confined to a wheelchair, and are able to walk 30 meters without the aid of a walker, crutches or cane
  • no changes in shoes or orthotic devices during the study period.

Exclusion Criteria

  • pregnancy or lactation in women
  • lower leg trauma other than ankle trauma
  • previous surgery involving the spine, hip or knee
  • the presence of an active joint infections of foot or ankle
  • previous surgery or arthroscopy on the ankle within 12 months
  • history of chicken or egg allergy
  • intraarticular steroid or hyaluronate injection in the treated ankle within the previous 6 months
  • treatment with anticoagulants or immunosuppressives
  • a history of rheumatoid arthritis, gout, or any other inflammatory arthropathy
  • the presence of other comorbidity (such as neoplasms, diabetes mellitus, paresis or recent trauma) or poor health status that would interfere with the clinical assessments during the study.

Arms & Interventions

The Botulinum Toxin A group

The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.

Intervention: Botulinum Toxin A (Allergan, Inc, Irvine CA)

The hyaluronate group (Hyalgan, Italy)

The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .

Intervention: Hyalgan (Hyalgan, Fidia , Italy)

Outcomes

Primary Outcomes

Ankle Osteoarthritis Scale (AOS) score

Time Frame: at 6 months after the injection

The AOS is a patient-rated, validated outcome measure that includes nine items on a pain subscale and nine items on a disability subscale.Using the AOS, a score of 0 represent no pain or disability and 10 represent worst pain or disability imaginable

Secondary Outcomes

  • adverse effects(at 2 weeks, 1 month, 3 months, and 6 months post injection.)
  • AOFAS ankle/hindfoot score(pre-injection and at 2 weeks, 1 month, 3 months, and 6 months post injection.)
  • Visual analog scale (VAS)(pre-injection and at 2 weeks, 1 month, 3 months, and 6 months post injection)
  • Single-leg stance test (SLS)(pre-injection and at 2 weeks, 1 month, 3 months, and 6 months post injection)
  • Timed " Up-and-Go" test (TUG)(pre-injection and at 2 weeks, 1 month, 3 months, and 6 months post injection)
  • global Patients satisfaction(at 2 weeks, 1 month, 3 months, and 6 months post injection.)

Study Sites (1)

Loading locations...

Similar Trials